SEC Form 4 · accession 0001193125-26-306110
Monte Rosa Therapeutics, Inc. · GLUE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jennifer Champoux
Officer — Chief Operating Officer
Period of report
Jul 15, 2026
Accepted (ET)
Jul 16, 2026 · 4:10 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001826457
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 15, 2026 | M | 4,351 | $3.98 | A | 66,722 | D | |
| Common StockF2 | Jul 15, 2026 | S | 4,351 | $23.3808 | D | 62,371 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $3.98 | Jul 15, 2026 | M | 4,351 | D | — | Jun 3, 2034 | Common Stock | 4,351 | 26,947 | D |
Explanation of responses
- F1These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 19, 2026.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.83 to $23.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F325% of the shares underlying this option vested on May 28, 2025, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.